PBYI Stock — Puma Biotechnology, Inc.

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 8 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$231.24M

Trailing 12 months

Net income (TTM)

$26.72M

Trailing 12 months

Revenue growth YoY

+7.8%

Year over year

Operating margin

13.2%

Trailing 12 months

P / E (TTM)

17.5

Trailing earnings · reciprocal yield 5.7%

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$93.90M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.9%

Year over year · more shares

Price change (1Y)

+102.7%

Trailing year

Short interest

8.3%

Latest settlement · 15.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Puma raised full-year 2026 NERLYNX net product revenue guidance to $205–$209M (from $202–$206M) and net income guidance to $17–$20M (from $16–$19M), but cut royalty guidance to $19–$22M from $20–$23M. Q2 product revenue rose to $53.6M from $49.2M a year ago, though new prescriptions fell 6% sequentially and the company is now debt-free after a final $11.1M loan payment.

Bullish

+ Raised full-year 2026 NERLYNX net product revenue guidance to $205–$209M from prior $202–$206M.
+ Raised full-year 2026 net income guidance to $17–$20M from prior $16–$19M.
+ Q2 2026 NERLYNX net product revenue rose to $53.6M from $49.2M in Q2 2025, with ex-factory bottles up 26% sequentially and 12% year-over-year.
+ Puma is now debt-free after paying off its 2021 Note Purchase Agreement, with $93.9M in cash and securities at quarter-end.
+ Alisertib ALISCA-Breast1 trial amended to focus on 40mg and 50mg dose groups, with updated interim data expected in Q4 2026.

Bearish

− Lowered full-year 2026 royalty guidance to $19–$22M from prior $20–$23M, with potential China generic threshold triggering further rate reduction in late 2026 or 2027.
− Q2 commercial new patient starts declined approximately 6% sequentially.
− Q2 gross-to-net adjustment widened to 27.9% from 27% in Q1 2026, driven by higher Medicaid share.
− R&D expenses rose to $18.9M in Q2 from $15.5M a year ago, with full-year R&D expected to grow 34%–37% year-over-year.
− Tax asset valuation allowance remains under review and could result in a future adjustment to net income.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +28%

above

Price vs 50-day avg +6%

above

RSI (14) 52

neutral

MACD trend Negative

52-week position 89%

near high

Momentum

relative strength

Very Strong

1-month return +5%

trailing

6-month return +49%

trailing

YTD return +53%

this year

Relative strength +31%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $9 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+2% holders QoQ · +21 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.28% of float · ▲ +2.6% MoM · 15.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

161 holders — near 3-yr high, broad support

Squeeze score 67

elevated · 0–100

Fundamentals

Strong

EPS growth −2%

Y/Y

Free cash flow $41.7M

Valuation P/E 17.5

in line

Balance sheet $7.1M

net cash

Quant / Vol

risk profile

Very High

Volatility 59%

annualized · 1-yr

Max drawdown −26%

past year

ATR 4.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

Third Quarter 2026

Net Product Revenue Initiated $54M – $56M

Royalty Revenue Initiated $2M – $3M

Total Revenue Initiated $56M – $59M

prior qtr $56.5M midpoint +1.8% QoQ

Net Income Initiated $2M – $3.5M

Gross to Net Adjustment Initiated 26% – 27%

New Full Year 2026

Net Product Revenue Initiated $205M – $209M

Royalty Revenue Initiated $19M – $22M

Total Revenue Initiated $224M – $231M

prior FY $228.37M midpoint −0.4% Y/Y

Net Income Initiated $17M – $20M

Gross to Net Adjustment Initiated 26.5% – 27.5%

Prior guidance period ended · from the Earnings Call filed Nov 4, 2021

Royalties from our partners · fiscal year 2021 $13M – $14M

NERLYNX net sales · Q4 2021 $42M – $44M

Royalty revenues · Q4 2021 $3.5M – $4.5M

Gross-to-net adjustment · Q4 2021 19.5% – 20.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+28% Bullish

Price vs 50-day avg

+6% Bullish

RSI (14)

52 Neutral

MACD trend

Negative Bearish

52-week position

89% Bullish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $9 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+2% holders QoQ · +21 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.28% of float · ▲ +2.6% MoM · 15.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

161 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $4 Now $9 · 89% Range high $10

vs 200-day avg +28% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PBYI Puma Biotechnology, Inc. this stock	$470.77M	+53.3%	-0.9%	17.5	8.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

161

% held: 75.1%
Net QoQ: +804.0K sh
Top holder: ACORN CAPITAL ADVISORS, L…

Held Float

View

Held by Funds

Fund positions

194

View

Short & Settlement

Short Interest Rising

Shares short

4.3M

Days to cover: 15.6d
Change: +106.7K sh

View

Short Volume

Short vol %

32%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

5.3K

Value: $43.3K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

35.9%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Donna Shalala

Amount: $1.0K–$15.0K
Traded: May 15, 2019

View

Financials

Revenue (FY)

$228.4M

Net income (FY): $31.1M
EPS diluted: $0.61

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 9

View

Proposed Sales

Value

$69.9K

Shares: 8.5K
Filed: Jul 6, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 14, 2026

Last call: Sep 9, 2026

View

Investor Relations

Upcoming events

1

View

	5D	20D	120D	MTD	YTD
PBYI	-3.1%	+4.7%	+49.0%	+0.1%	+53.3%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-1.9%	+6.5%	+31.2%	+0.5%	+41.2%

PBYI · Puma Biotechnology, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance